Thetis Pharmaceuticals Announces U.S. Patent Grant for TP-317, Its First-in-Class Oral BLT1 Agonist for IBD and Oncology
New Patent Extends IP Protection to 2048
ESSEX, Conn. — March 3, 2026 — Thetis Pharmaceuticals, LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD) and oncology, today announced that the U.S. Patent and Trademark Office has granted U.S. Pat # 12,564,644, providing pharmaceutical composition and method of use protection for TP-317, with a base expiration date in March 2043 and prospects for patent term extension to 2048.
“As an add-on to approved therapies, TP-317 is designed to increase response rates and durability, while extending the lifecycle of combination therapies into the late 2040s. In IBD, TP-317 provides a non-immunosuppressive mechanism of action, directly promoting epithelial repair to complement the mucosal healing achieved with advanced immunomodulators,” said Gary Mathias, co-founder and CEO of Thetis. “In oncology, TP-317 activates the critical immune responses upstream of immune checkpoint inhibitors (ICI) that are required for ICI to work for more patients.”
About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing new therapies for IBD and oncology. Thetis' lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug candidate that engages the BLT1 receptor to activate the body’s natural ability to restore tissue and immune homeostasis. In a Phase 1a study, TP-317 was well tolerated and demonstrated target engagement. A Phase 1b proof-of-mechanism trial in ulcerative colitis patients is set to begin in late 2026. Thetis is supported by the Helmsley Charitable Trust, the Crohn's & Colitis Foundation, the Kenneth Rainin Foundation, the National Institutes of Health (NIH), and private investors.
Contact Information
Tracy Lessor
TLOW Communications
617-519-9827
tracy@tlowcommunications.com